| Literature DB >> 18382669 |
Liwen Chen1, Edward E Tredget, Philip Y G Wu, Yaojiong Wu.
Abstract
Bone marrow derived mesenchymal stem cells (BM-MSCs) have been shown to enhance wound healing; however, the mechanisms involved are barely understood. In this study, we examined paracrine factors released by BM-MSCs and their effects on the cells participating in wound healing compared to those released by dermal fibroblasts. Analyses of BM-MSCs with Real-Time PCR and of BM-MSC-conditioned medium by antibody-based protein array and ELISA indicated that BM-MSCs secreted distinctively different cytokines and chemokines, such as greater amounts of VEGF-alpha, IGF-1, EGF, keratinocyte growth factor, angiopoietin-1, stromal derived factor-1, macrophage inflammatory protein-1alpha and beta and erythropoietin, compared to dermal fibroblasts. These molecules are known to be important in normal wound healing. BM-MSC-conditioned medium significantly enhanced migration of macrophages, keratinocytes and endothelial cells and proliferation of keratinocytes and endothelial cells compared to fibroblast-conditioned medium. Moreover, in a mouse model of excisional wound healing, where concentrated BM-MSC-conditioned medium was applied, accelerated wound healing occurred compared to administration of pre-conditioned or fibroblast-conditioned medium. Analysis of cell suspensions derived from the wound by FACS showed that wounds treated with BM-MSC-conditioned medium had increased proportions of CD4/80-positive macrophages and Flk-1-, CD34- or c-kit-positive endothelial (progenitor) cells compared to wounds treated with pre-conditioned medium or fibroblast-conditioned medium. Consistent with the above findings, immunohistochemical analysis of wound sections showed that wounds treated with BM-MSC-conditioned medium had increased abundance of macrophages. Our results suggest that factors released by BM-MSCs recruit macrophages and endothelial lineage cells into the wound thus enhancing wound healing.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18382669 PMCID: PMC2270908 DOI: 10.1371/journal.pone.0001886
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Surface marker profile of dermal fibroblasts and BM-MSCs
| Dermal fibroblasts | BM-MSCs | |
| CD45 | − | − |
| CD34 | − | − |
| Flk-1 (VEGFR-2) | − | − |
| CD90 (Thy-1) | ++++ | ++++ |
| CD44 | ++++ | ++++ |
| CD73 (SH4, ecto-5′-nucleosidase) | ++++ | ++++ |
| CD105 (SH2, endoglin) | +++ | ++++ |
|
| −/+ | ++++ |
Representative results of three FACS analyses of murine dermal fibroblasts and BM-MSCs. − ∼ ++++ represent percentages of cells expressing surface markers as indicated: “−” ≤ 2%; “+” 3∼10%; “++” 11∼50%; “+++” 51∼90%; “++++” 91∼100%.
Murine primers for Real-Time PCR
| FORWARD | REVERSE | ||
| Vascular endothelial growth factor-α | VEGFa |
|
|
| Epidermal growth factor | EGF |
|
|
| keratinocyte growth factor | KGF |
|
|
| Insulin-like growth factor | IGF |
|
|
| heparin-binding EGF-like growth factor | HB-EGF |
|
|
| Basic fibroblast growth factor | bFGF |
|
|
| Transforming growth factor beta1 | TGFβ1 |
|
|
| stromal derived factor-1 | SDF-1 |
|
|
| stem cell factor | SCF |
|
|
| erythropoietin | EPO |
|
|
| granulocyte colony stimulating factor | G-CSF |
|
|
| Thrombopoietin-1 | TPO |
|
|
| Monocyte chemotactic protein-1 | MCP-1 |
|
|
| macrophage inflammatory protein1a | MIP1a |
|
|
| macrophage inflammatory protein1b | MIP1b |
|
|
| monokine induced by gama interferon | MIG |
|
|
| gama interferon-inducible protein-10 | CXCL10 |
|
|
| glyceraldehyde-3-phosphate-dehydrogenase | GAPDH |
|
|
Figure 1mRNA levels of cytokines and extracellular matrix molecules in BM-MSCs and fibroblasts.
Total RNA extracted from BM-MSCs (MSC) or dermal fibroblasts (FB) treated under hypoxic conditions was analyzed by Real-Time PCR for mRNA expression of genes as indicated in the figure. Fold changes vs dermal fibroblasts are shown. Data are mean±SD; n = 3; *P<0.05 vs FB. KGF, keratinocyte growth factor; HB-EGF, heparin-binding EGF-like growth factor; TGFb1, Transforming growth factor-β1; Ang, angiopoietin; SDF1, stromal cell-derived factor-1; MIP, macrophage inflammatory protein; SCF, stem cell factor; EPO, erythropoietin; TPO, thrombopoietin; G-CSF, granulocyte colony stimulating factor; MCP1, monocyte chemotactic protein-1; MIG, monokine induced by gama interferon.
Figure 2Protein levels of cytokines in BM-MSC-conditioned medium.
(A) Antibody-based protein array analysis human dermal fibroblast (FB)- or BM-MSC-conditioned medium under hypoxic conditions. Similar results were obtained from three independent experiments and results from one of them are shown. The abbreviations are donated in Table 2. (B) ELISA measurement of cytokines in murine fibroblast- or BM-MSC- conditioned medium under hypoxic conditions. Data are expressed as means±SD (n = 3, *P<0.01). PDGF-BB, platelet-derived growth factor-BB. Other abbreviations can be found in the legend for Figure 1.
Antibody-based protein array analysis of fibroblast- or MSC-conditioned medium
| human fibroblast | human MSC | mouse fibroblast | mouse MSCs | hypoxia/normoxia | ||
| Epithelial-neutrophil activating peptide | ENA-78 | + | + | N/A | N/A | NC |
| Granulocyte colony-stimulating factor | G-CSF | + | + | +/− | +/− | NC |
| Granulocyte-macrophage colony-stimulating factor | GM-CSF | +/− | +/− | + | + | NC |
| Growth-related oncogene | GRO | ++ | + | N/A | N/A | NC |
| Growth-related oncogene α, CXCL1 | GRO-α | +/− | +/− | + | +++ | NC |
| CCL1 | I-309 | + | + | N/A | N/A | NC |
| Interleukin-1α | IL-1α | ++ | ++ | N/A | N/A | NC |
| Interleukin-1β | IL-1β | + | + | N/A | N/A | NC |
| Interleukin-2 | IL-2 | + | + | +/− | +/− | NC |
| Interleukin-3 | IL-3 | + | + | +/− | +/− | NC |
| Interleukin-4 | IL-4 | + | + | + | + | NC |
| Interleukin-5 | IL-5 | +/− | +/− | +/− | +/− | NC |
| Interleukin-6 | IL-6 | ++++ | +++ | +++ | ++ | NC |
| Interleukin-7 | IL-7 | +/− | +/− | N/A | N/A | NC |
| Interleukin-8 | IL-8 | ++ | ++ | N/A | N/A | NC |
| Interleukin-10 | IL-10 | + | + | +/− | +/− | NC |
| Interleukin-12 | IL-12 | + | + | +/− | +/− | NC |
| Interleukin-13 | IL-13 | +/− | +/− | + | + | NC |
| Interleukin-15 | IL-15 | +/− | +/− | N/A | N/A | NC |
| Interferon γ | IFN-γ | +/− | +/− | +/− | +/− | NC |
| Monocyte chemoattractant protein-1, CCL2 | MCP-1 | ++ | ++ | +++ | +++ | NC |
| Monocyte chemoattractant protein-2, CCL8 | MCP-2 | +/− | +/− | N/A | N/A | NC |
| Monocyte chemoattractant protein-3, CCL7 | MCP-3 | +/− | +/− | N/A | N/A | NC |
| macrophage colony-stimulating factor | M-CSF | + | + | N/A | N/A | NC |
| Macrophage Derived Chemokine | MDC | + | + | N/A | N/A | NC |
| Monokine induced by IFN-Gamma, CXCL9 | MIG | +/− | +/− | N/A | N/A | NC |
| Macrophage inhibitory protein-1β, CCL4 | MIP-1β | + | ++ | N/A | N/A | NC |
| Macrophage inhibitory protein-1δ | MIP-1δ | + | + | N/A | N/A | NC |
| Regulated on activation normal T cell-expressed and secreted, CCL5 | RANTES | + | + | + | + | NC |
| Stem cell factor | SCF | + | + | +/− | +/− | NC |
| Stromal cell-derived factor 1 | SDF-1 | + | + | N/A | N/A | NC |
| Thymus- and activation-related chemokine, CCL17 | TARC | +/− | +/− | + | + | NC |
| Transforming Growth Factor-b1 | TGF-β1 | +/− | +/− | N/A | N/A | NC |
| Tumor necrosis factor-α | TNF-α | + | + | +/− | +/− | NC |
| Tumor necrosis factor-β | TNF-β | + | + | N/A | N/A | NC |
| Epidermal growth factor | EGF | +/− | + | N/A | N/A | NC |
| Insulin-like growth factor-1 | IGF-1 | + | ++ | N/A | N/A | NC |
| Angiopoietin | Ang | +++ | ++++ | N/A | N/A | up |
| Oncostatin M | OSM | + | ++ | N/A | N/A | up |
| Thrombopoietin | TPO | + | ++ | + | + | up |
| Vascular endothelial growth factor | VEGF | ++ | ++++ | ++ | +++ | up |
| Platelet derived growth factor-BB | PDGF-BB | +/− | + | N/A | N/A | up |
| Leptin | Leptin | +/− | + | +/− | +/− | up |
| Brain derived neurotrophic factor | BDNF | + | ++ | N/A | N/A | up |
| B Lymphocyte Chemoattractant, CXCL13 | BLC | +/− | +/− | N/A | N/A | NC |
| CCL23 | Ck β 8-1 | +/− | +/− | N/A | N/A | NC |
| Eotaxin | Eotaxin | +/− | +/− | +/− | +/− | NC |
| Eotaxin-2 | Eotaxin-2 | +/− | +/− | N/A | N/A | NC |
| Eotaxin-3 | Eotaxin-3 | + | + | N/A | N/A | down |
| Fibroblast growth factor-4 | FGF-4 | − | + | N/A | N/A | NC |
| Fibroblast growth factor-6 | FGF-6 | +/− | + | N/A | N/A | NC |
| Fibroblast growth factor-7 | FGF-7 | +/− | + | N/A | N/A | NC |
| Fibroblast growth factor-9 | FGF-9 | + | ++ | N/A | N/A | NC |
| FMS-related tyrosine kinase 3 ligand | Flt-3 ligand | +/− | + | N/A | N/A | NC |
| Fractalkine | Fractalkine | + | ++ | N/A | N/A | up |
| granulocyte chemotactic protein-2 | GCP-2 | +/− | +/− | N/A | N/A | NC |
| Glial cell line-derived neurotrophic factor | GDNF | + | ++ | N/A | N/A | NC |
| hepatocyte growth factor | HGF | ++ | +++ | N/A | N/A | up |
| IGF binding protein-1 | IGFBP-1 | +/− | + | N/A | N/A | NC |
| IGF binding protein-2 | IGFBP-2 | ++ | ++ | N/A | N/A | NC |
| IGF binding protein-3 | IGFBP-3 | + | ++ | N/A | N/A | NC |
| IGF binding protein-4 | IGFBP-4 | + | ++ | N/A | N/A | NC |
| interleukin 16 | IL-16 | +/− | +/− | N/A | N/A | NC |
| Interferon-inducible protein of 10 kDa, CXCL10 | IP-10 | + | + | N/A | N/A | NC |
| Leukaemia inhibitory factor | LIF | + | ++ | N/A | N/A | NC |
| Tumor necrosis factor (ligand) super family, member 14 | LIGHT | + | + | N/A | N/A | NC |
| CCL13 | MCP-4 | +/− | +/− | N/A | N/A | NC |
| Macrophage migration inhibitory factor | MIF | +/− | +/− | N/A | N/A | NC |
| macrophage inflammatory protein-3α | MIP-3α | +/− | + | N/A | N/A | NC |
| Neutrophil-activating peptide-2 | NAP-2 | + | ++ | N/A | N/A | up |
| Neurotrophin 3 | NT-3 | + | + | N/A | N/A | up |
| Neurotrophin 4 | NT-4 | + | + | N/A | N/A | up |
| Osteoprotegrin | OPTGRN | ++++ | ++ | N/A | N/A | NC |
| CCL18 | PARC | + | + | N/A | N/A | NC |
| Placenta growth factor | PIGF | ++ | ++ | N/A | N/A | NC |
| Transforming Growth Factor-b2 | TGF-β2 | ++ | + | N/A | N/A | NC |
| Transforming Growth Factor-b3 | TGF-β3 | ++ | + | N/A | N/A | NC |
| Metalloproteinase inhibitor-1 | TIMP-1 | ++++ | ++++ | + | + | NC |
| Metalloproteinase inhibitor-2 | TIMP-2 | ++++ | ++++ | N/A | N/A | NC |
| 6Ckine, CCL21 | 6Ckine | N/A | N/A | +/− | +/− | NC |
| Cutaneous T-cell-attracting chemokine, CCL27 | CTACK | N/A | N/A | + | + | NC |
| IL12p70 | IL12p70 | N/A | N/A | + | + | NC |
| Interleukin-17 | IL17 | N/A | N/A | +/− | +/− | NC |
| Monocyte chemoattractant protein-5, CCL12 | MCP-5 | N/A | N/A | + | ++ | NC |
| Macrophage inflammatory protein-1α | MIP-1α | N/A | N/A | + | + | NC |
| Macrophage inflammatory protein-2 | MIP-2 | N/A | N/A | + | +++ | NC |
| Macrophage inflammatory protein-3b | MIP-3b | N/A | N/A | + | + | NC |
| Soluble tumor necrosis factor receptor 1 | sTNF-R1 | N/A | N/A | ++ | +++ | NC |
Human or murine dermal fibroblast- or BM-MSC-conditioned medium under hypoxic conditions for 24 h was analyzed with antibody-based protein array. The intensity of each dot was measured. “−”, not detected; +/−, weakly detected; + ∼ ++++, intensity of positive detection; N/A, not tested; protein levels in medium under hypoxic conditions are indicated as up, down or NC (no change) compared to normoxic conditions.
Figure 3Effects of BM-MSC-conditioned medium on cell migration and proliferation.
(A) migration of CD14+ monocytes. CD14+ monocytes were isolated as described in “Methods” and equal numbers of the cells were loaded to the top chambers. Control (CTL) vehicle medium, fibroblast (FB-M)- or BM-MSC (MSC-M)-conditioned medium at different concentrations were added to the bottom chambers. Cells migrated into the bottom chambers were counted. Triple wells were used. Data shown represent mean±SD of 3 independent experiments (P<0.01). (B) Keratinocyte migration. Equal numbers of murine dermal keratinocytes were added to the top chambers. Media in the bottom chambers were as indicated. Cells migrated to the down-side of the filter were stained, photographed (6 fields per well) and counted. Triple wells were used for each treatment and data shown represent mean±SD of 3 independent experiments (P<0.001). (C) Keratinocyte proliferation. 0.5×105 murine dermal keratinocytes per well were incubated with vehicle-M, FB-M, MSC-M or keratinocyte SFM supplemented with EGF (5 ng/ml, EGF) for different times and cell numbers were counted. Triple wells were used for each treatment. Values shown represent mean±SD of 4 independent experiments (* P<0.01). (D) HUVEC migration. The bottom chambers contained vehicle-M, FB-M or MSC-M at various dilutions. Cells migrated to the down-side of the filter were stained, photographed (6 fields per well) and counted. Triple wells were used for each treatment and data shown represent mean±SD of three independent experiments (*P<0.01 vs vehicle-M; #P<0.01 vs FB-M) (E) HUVEC proliferation. Equal numbers of HUVECs were grown in vehicle-, FB- or MSC-conditioned basal endothelial growth medium (EGM-2) supplemented with 2% FBS or complete EGM-2 and incubated for 3 days. Cell numbers were counted. Experiments were performed in triplicate wells (n = 3, * P<0.001).
Figure 4Effect of BM-MSC-conditioned medium on wound closure.
(A) Representative images of wounds before treatment or 7 days after treatment with vehicle control medium (vehicle-M), concentrated fibroblast (FB-M)- or BM-MSC-conditioned medium (MSC-M). (B) Measurement of wound sizes at different times (n = 6 to 13, *P<0.05, **P<0.001).
Figure 5Analysis of cells in wounds.
(A) FACS analysis of cells derived from each wound indicated that wounds treated with concentrated BM-MSC-conditioned medium (MSC-M) at 7 or 14 days had increased percentages of CD4/80 positive monocytes/macrophages compared to wounds treated with vehicle control medium (vehicle-M) or concentrated fibroblast-conditioned medium (FB-M). (B&C) Percentages of cells in wound after FACS analysis (n = 5∼6, *P<0.05). (D) Representative images of confocal microscopy of day 7 wounds treated with vehicle medium, concentrated fibroblast- or BM-MSC-conditioned medium after immunostaining for CD68 (red). Nuclei were stained blue with Hoechst. scale bar, 20 µm.